Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: J Autoimmun. 2018 Aug 8;94:122–133. doi: 10.1016/j.jaut.2018.07.022

Fig. 6. Pharmacological inhibition of MDR1/MRP4 enhances immunoregulatory effects of UCB in DSS colitis.

Fig. 6.

WT mice (n=24) were treated with 3% DSS for 6 days and sacrificed on day 7. In additional n=24 mice, DSS treatment was replaced with normal water for additional 4 days. For the whole duration of experiment, mice were administered vehicle (n=12), UCB (n=12), RTV (n=12), or UCB plus RTV (n=12). (A) Mean ± SEM weight score in vehicle, UCB, RTV and UCB plus RTV-treated WT mice. (B) Mean ± SEM colon length (cm) on days 7 and 10. (C) Representative hematoxylin & eosin staining of colon sections. Mean ± SEM histology score on days 7 and 10 is also shown. Comparisons were made using one-way ANOVA, followed by Tukey’s multiple comparison test. *P≤0.05;**P≤0.01;***P≤0.001.